ID   IMPA1_HUMAN             Reviewed;         277 AA.
AC   P29218; B2R733; B4DLN3; B7Z6Q4; J3KQT7; Q9UK71;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-1992, sequence version 1.
DT   10-MAY-2017, entry version 188.
DE   RecName: Full=Inositol monophosphatase 1;
DE            Short=IMP 1;
DE            Short=IMPase 1;
DE            EC=3.1.3.25 {ECO:0000269|PubMed:1377913, ECO:0000269|PubMed:17068342, ECO:0000269|PubMed:8068620, ECO:0000269|PubMed:8718889, ECO:0000269|PubMed:9462881};
DE   AltName: Full=D-galactose 1-phosphate phosphatase {ECO:0000303|PubMed:9462881};
DE            EC=3.1.3.94 {ECO:0000269|PubMed:9462881};
DE   AltName: Full=Inositol-1(or 4)-monophosphatase 1;
DE   AltName: Full=Lithium-sensitive myo-inositol monophosphatase A1;
GN   Name=IMPA1; Synonyms=IMPA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CATALYTIC ACTIVITY.
RC   TISSUE=Hippocampus;
RX   PubMed=1377913; DOI=10.1042/bj2840749;
RA   McAllister G., Whiting P., Hammond E.A., Knowles M.R., Atack J.R.,
RA   Bailey F.J., Maigetter R., Ragan C.I.;
RT   "cDNA cloning of human and rat brain myo-inositol monophosphatase.
RT   Expression and characterization of the human recombinant enzyme.";
RL   Biochem. J. 284:749-754(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9339367; DOI=10.1006/geno.1997.4862;
RA   Sjoeholt G., Molven A., Loevlie R., Wilcox A., Sikela J.M.,
RA   Steen V.M.;
RT   "Genomic structure and chromosomal localization of a human myo-
RT   inositol monophosphatase gene (IMPA).";
RL   Genomics 45:113-122(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Parthasarathy R., Parthasarathy L., Vadnal R.E.;
RT   "Molecular cloning and expression of human cerebral cortex myo-
RT   inositol monophosphatase A1 cDNA.";
RL   Submitted (JAN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Thymus, and Umbilical cord blood;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-20.
RA   Parthasarathy L., Parthasarathy R.;
RT   "Molecular cloning, genomic organization and promoter analysis of the
RT   human brain lithium-sensitive myo-inositol monophosphatase A1
RT   isoenzyme.";
RL   Submitted (MAY-2000) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, ENZYME REGULATION, AND
RP   SUBUNIT.
RX   PubMed=9462881; DOI=10.1016/S0006-8993(97)01042-1;
RA   Parthasarathy R., Parthasarathy L., Vadnal R.;
RT   "Brain inositol monophosphatase identified as a galactose 1-
RT   phosphatase.";
RL   Brain Res. 778:99-106(1997).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES,
RP   ENZYME REGULATION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-93.
RX   PubMed=17068342; DOI=10.1074/jbc.M604474200;
RA   Ohnishi T., Ohba H., Seo K.-C., Im J., Sato Y., Iwayama Y.,
RA   Furuichi T., Chung S.-K., Yoshikawa T.;
RT   "Spatial expression patterns and biochemical properties distinguish a
RT   second myo-inositol monophosphatase IMPA2 from IMPA1.";
RL   J. Biol. Chem. 282:637-646(2007).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-168, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   INVOLVEMENT IN MRT59.
RX   PubMed=26416544; DOI=10.1038/mp.2015.150;
RA   Figueiredo T., Melo U.S., Pessoa A.L., Nobrega P.R., Kitajima J.P.,
RA   Rusch H., Vaz F., Lucato L.T., Zatz M., Kok F., Santos S.;
RT   "A homozygous loss-of-function mutation in inositol monophosphatase 1
RT   (IMPA1) causes severe intellectual disability.";
RL   Mol. Psychiatry 21:1125-1129(2016).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) IN COMPLEX WITH GADOLINIUM IONS,
RP   METAL-BINDING SITE, AND SUBUNIT.
RX   PubMed=1332026; DOI=10.1073/pnas.89.21.10031;
RA   Bone R., Springer J.P., Atack J.R.;
RT   "Structure of inositol monophosphatase, the putative target of lithium
RT   therapy.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:10031-10035(1992).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) IN COMPLEX WITH MYO-INOSITOL
RP   1-PHOSPHATE AND GADOLINIUM ION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, SUBUNIT, METAL-BINDING SITE, AND MUTAGENESIS OF SER-165
RP   AND GLU-213.
RX   PubMed=8068620; DOI=10.1021/bi00198a011;
RA   Bone R., Frank L., Springer J.P., Pollack S.J., Osborne S.A.,
RA   Atack J.R., Knowles M.R., McAllister G., Ragan C.I., Broughton H.B.;
RT   "Structural analysis of inositol monophosphatase complexes with
RT   substrates.";
RL   Biochemistry 33:9460-9467(1994).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) IN COMPLEXES WITH SUBSTRATE
RP   ANALOG AND MANGANESE, AND COFACTOR.
RX   PubMed=8068621; DOI=10.1021/bi00198a012;
RA   Bone R., Frank L., Springer J.P., Atack J.R.;
RT   "Structural studies of metal binding by inositol monophosphatase:
RT   evidence for two-metal ion catalysis.";
RL   Biochemistry 33:9468-9476(1994).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF MUTANT GLN-36, MUTAGENESIS OF
RP   LYS-36, CATALYTIC ACTIVITY, FUNCTION, COFACTOR, AND ENZYME REGULATION.
RX   PubMed=8718889; DOI=10.1021/bi9603837;
RA   Ganzhorn A.J., Lepage P., Pelton P.D., Strasser F., Vincendon P.,
RA   Rondeau J.-M.;
RT   "The contribution of lysine-36 to catalysis by human myo-inositol
RT   monophosphatase.";
RL   Biochemistry 35:10957-10966(1996).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH 1D-MYO-INOSITOL
RP   1-PHOSPHATE AND CALCIUM, AND METAL-BINDING SITE.
RA   Ganzhorn A.J., Rondeau J.-M.;
RT   "Structure of an enzyme-substrate complex and the catalytic mechanism
RT   of human brain myo-inositol monophosphatase.";
RL   Protein Eng. 10:61-70(1997).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) IN COMPLEX WITH MAGNESIUM,
RP   COFACTOR, AND SUBUNIT.
RX   PubMed=23027737; DOI=10.1107/S1744309112035191;
RA   Singh N., Halliday A.C., Knight M., Lack N.A., Lowe E.,
RA   Churchill G.C.;
RT   "Cloning, expression, purification, crystallization and X-ray analysis
RT   of inositol monophosphatase from Mus musculus and Homo sapiens.";
RL   Acta Crystallogr. F 68:1149-1152(2012).
CC   -!- FUNCTION: Responsible for the provision of inositol required for
CC       synthesis of phosphatidylinositol and polyphosphoinositides and
CC       has been implicated as the pharmacological target for lithium
CC       action in brain. Has broad substrate specificity and can use myo-
CC       inositol monophosphates, myo-inositol 1,3-diphosphate, myo-
CC       inositol 1,4-diphosphate, scyllo-inositol-phosphate, D-galactose
CC       1-phosphate, glucose-1-phosphate, glucose-6-phosphate, fructose-1-
CC       phosphate, beta-glycerophosphate, and 2'-AMP as substrates.
CC       {ECO:0000269|PubMed:17068342, ECO:0000269|PubMed:8718889,
CC       ECO:0000269|PubMed:9462881}.
CC   -!- CATALYTIC ACTIVITY: Myo-inositol phosphate + H(2)O = myo-inositol
CC       + phosphate. {ECO:0000269|PubMed:1377913,
CC       ECO:0000269|PubMed:8068620, ECO:0000269|PubMed:8718889,
CC       ECO:0000269|PubMed:9462881}.
CC   -!- CATALYTIC ACTIVITY: Alpha-D-galactose 1-phosphate + H(2)O = D-
CC       galactose + phosphate. {ECO:0000269|PubMed:9462881}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:17068342,
CC         ECO:0000269|PubMed:8718889, ECO:0000269|PubMed:9462881,
CC         ECO:0000303|PubMed:23027737, ECO:0000303|PubMed:8068621};
CC   -!- ENZYME REGULATION: Activity with myo-inositol monophosphate and D-
CC       galactose 1-phosphate is inhibited by Li(+), Ca(2+) and Mn(2+),
CC       but also by Mg(2+) at concentrations above 3 mM.
CC       {ECO:0000269|PubMed:17068342, ECO:0000269|PubMed:8718889,
CC       ECO:0000269|PubMed:9462881}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=42 uM for D-myo-inositol 1-phosphate
CC         {ECO:0000269|PubMed:8068620};
CC         KM=62 uM for L-myo-inositol 1-phosphate
CC         {ECO:0000269|PubMed:8068620};
CC       pH dependence:
CC         Optimum pH is 7.0-7.5. {ECO:0000269|PubMed:17068342};
CC   -!- PATHWAY: Polyol metabolism; myo-inositol biosynthesis; myo-
CC       inositol from D-glucose 6-phosphate: step 2/2.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:1332026,
CC       ECO:0000269|PubMed:23027737, ECO:0000269|PubMed:8068620,
CC       ECO:0000269|PubMed:8068621, ECO:0000269|PubMed:9462881}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-752410, EBI-752410;
CC       O14732:IMPA2; NbExp=3; IntAct=EBI-752410, EBI-725233;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17068342}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P29218-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P29218-2; Sequence=VSP_042521;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=P29218-3; Sequence=VSP_046308;
CC         Note=No experimental confirmation available. Ref.4 (BAH13340)
CC         sequence is in conflict in position: 17:Q->R. {ECO:0000305};
CC   -!- DISEASE: Mental retardation, autosomal recessive 59 (MRT59)
CC       [MIM:617323]: A form of mental retardation, a disorder
CC       characterized by significantly below average general intellectual
CC       functioning associated with impairments in adaptive behavior and
CC       manifested during the developmental period. MRT59 transmission
CC       pattern is consistent with autosomal recessive inheritance.
CC       {ECO:0000269|PubMed:26416544}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the inositol monophosphatase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X66922; CAA47359.1; -; mRNA.
DR   EMBL; Y11360; CAA72195.1; -; Genomic_DNA.
DR   EMBL; Y11361; CAA72195.1; JOINED; Genomic_DNA.
DR   EMBL; Y11362; CAA72195.1; JOINED; Genomic_DNA.
DR   EMBL; Y11367; CAA72195.1; JOINED; Genomic_DNA.
DR   EMBL; Y11363; CAA72195.1; JOINED; Genomic_DNA.
DR   EMBL; Y11364; CAA72195.1; JOINED; Genomic_DNA.
DR   EMBL; Y11365; CAA72195.1; JOINED; Genomic_DNA.
DR   EMBL; Y11366; CAA72195.1; JOINED; Genomic_DNA.
DR   EMBL; AF042729; AAB97468.1; -; mRNA.
DR   EMBL; AK297078; BAG59595.1; -; mRNA.
DR   EMBL; AK300750; BAH13340.1; -; mRNA.
DR   EMBL; AK312823; BAG35680.1; -; mRNA.
DR   EMBL; AC090255; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471068; EAW87095.1; -; Genomic_DNA.
DR   EMBL; BC008381; AAH08381.1; -; mRNA.
DR   EMBL; BC009565; AAH09565.1; -; mRNA.
DR   EMBL; AF178754; AAD52997.1; -; Genomic_DNA.
DR   CCDS; CCDS47883.1; -. [P29218-3]
DR   CCDS; CCDS47884.1; -. [P29218-2]
DR   CCDS; CCDS6231.1; -. [P29218-1]
DR   PIR; S23130; S23130.
DR   RefSeq; NP_001138350.1; NM_001144878.1. [P29218-3]
DR   RefSeq; NP_001138351.1; NM_001144879.1. [P29218-2]
DR   RefSeq; NP_005527.1; NM_005536.3. [P29218-1]
DR   UniGene; Hs.656694; -.
DR   PDB; 1AWB; X-ray; 2.50 A; A/B=2-277.
DR   PDB; 1IMA; X-ray; 2.30 A; A/B=1-277.
DR   PDB; 1IMB; X-ray; 2.20 A; A/B=1-277.
DR   PDB; 1IMC; X-ray; 2.60 A; A/B=1-277.
DR   PDB; 1IMD; X-ray; 2.60 A; A/B=1-277.
DR   PDB; 1IME; X-ray; 2.25 A; A/B=1-277.
DR   PDB; 1IMF; X-ray; 2.50 A; A=1-277.
DR   PDB; 2HHM; X-ray; 2.10 A; A/B=2-277.
DR   PDB; 4AS4; X-ray; 1.70 A; A/B=1-277.
DR   PDBsum; 1AWB; -.
DR   PDBsum; 1IMA; -.
DR   PDBsum; 1IMB; -.
DR   PDBsum; 1IMC; -.
DR   PDBsum; 1IMD; -.
DR   PDBsum; 1IME; -.
DR   PDBsum; 1IMF; -.
DR   PDBsum; 2HHM; -.
DR   PDBsum; 4AS4; -.
DR   ProteinModelPortal; P29218; -.
DR   SMR; P29218; -.
DR   BioGrid; 109825; 23.
DR   IntAct; P29218; 3.
DR   MINT; MINT-1480285; -.
DR   STRING; 9606.ENSP00000408526; -.
DR   ChEMBL; CHEMBL1786; -.
DR   DrugBank; DB03542; L-Myo-Inositol-1-Phosphate.
DR   DrugBank; DB01356; Lithium.
DR   GuidetoPHARMACOLOGY; 1463; -.
DR   DEPOD; P29218; -.
DR   iPTMnet; P29218; -.
DR   PhosphoSitePlus; P29218; -.
DR   SwissPalm; P29218; -.
DR   BioMuta; IMPA1; -.
DR   DMDM; 127717; -.
DR   REPRODUCTION-2DPAGE; IPI00020906; -.
DR   UCD-2DPAGE; P29218; -.
DR   EPD; P29218; -.
DR   MaxQB; P29218; -.
DR   PaxDb; P29218; -.
DR   PeptideAtlas; P29218; -.
DR   PRIDE; P29218; -.
DR   DNASU; 3612; -.
DR   Ensembl; ENST00000256108; ENSP00000256108; ENSG00000133731. [P29218-1]
DR   Ensembl; ENST00000311489; ENSP00000311803; ENSG00000133731. [P29218-2]
DR   Ensembl; ENST00000449740; ENSP00000408526; ENSG00000133731. [P29218-3]
DR   GeneID; 3612; -.
DR   KEGG; hsa:3612; -.
DR   UCSC; uc003ych.3; human. [P29218-1]
DR   CTD; 3612; -.
DR   DisGeNET; 3612; -.
DR   GeneCards; IMPA1; -.
DR   HGNC; HGNC:6050; IMPA1.
DR   HPA; HPA037489; -.
DR   MIM; 602064; gene.
DR   MIM; 617323; phenotype.
DR   neXtProt; NX_P29218; -.
DR   OpenTargets; ENSG00000133731; -.
DR   PharmGKB; PA29860; -.
DR   eggNOG; KOG2951; Eukaryota.
DR   eggNOG; COG0483; LUCA.
DR   GeneTree; ENSGT00390000014699; -.
DR   HOGENOM; HOG000282238; -.
DR   HOVERGEN; HBG052123; -.
DR   InParanoid; P29218; -.
DR   KO; K01092; -.
DR   OMA; KIEFGIV; -.
DR   OrthoDB; EOG091G0D21; -.
DR   PhylomeDB; P29218; -.
DR   TreeFam; TF313194; -.
DR   BioCyc; MetaCyc:HS05783-MONOMER; -.
DR   Reactome; R-HSA-1855183; Synthesis of IP2, IP, and Ins in the cytosol.
DR   SABIO-RK; P29218; -.
DR   UniPathway; UPA00823; UER00788.
DR   ChiTaRS; IMPA1; human.
DR   EvolutionaryTrace; P29218; -.
DR   GeneWiki; IMPA1; -.
DR   GenomeRNAi; 3612; -.
DR   PRO; PR:P29218; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000133731; -.
DR   CleanEx; HS_IMPA1; -.
DR   ExpressionAtlas; P29218; baseline and differential.
DR   Genevisible; P29218; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008934; F:inositol monophosphate 1-phosphatase activity; IDA:MGI.
DR   GO; GO:0052832; F:inositol monophosphate 3-phosphatase activity; TAS:Reactome.
DR   GO; GO:0052833; F:inositol monophosphate 4-phosphatase activity; TAS:Reactome.
DR   GO; GO:0052834; F:inositol monophosphate phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0031403; F:lithium ion binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:MGI.
DR   GO; GO:0006021; P:inositol biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0006020; P:inositol metabolic process; IBA:GO_Central.
DR   GO; GO:0046855; P:inositol phosphate dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   GO; GO:0006796; P:phosphate-containing compound metabolic process; IMP:UniProtKB.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0046854; P:phosphatidylinositol phosphorylation; IEA:InterPro.
DR   GO; GO:0007165; P:signal transduction; IMP:UniProtKB.
DR   CDD; cd01639; IMPase; 1.
DR   InterPro; IPR033942; IMPase.
DR   InterPro; IPR020583; Inositol_monoP_metal-BS.
DR   InterPro; IPR020552; Inositol_monoPase_Li-sen.
DR   InterPro; IPR000760; Inositol_monophosphatase-like.
DR   InterPro; IPR020550; Inositol_monophosphatase_CS.
DR   PANTHER; PTHR20854; PTHR20854; 1.
DR   Pfam; PF00459; Inositol_P; 1.
DR   PRINTS; PR00377; IMPHPHTASES.
DR   PRINTS; PR00378; LIIMPHPHTASE.
DR   PROSITE; PS00629; IMP_1; 1.
DR   PROSITE; PS00630; IMP_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Hydrolase; Lithium; Magnesium; Mental retardation; Metal-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome.
FT   CHAIN         1    277       Inositol monophosphatase 1.
FT                                /FTId=PRO_0000142513.
FT   REGION       92     95       Substrate binding.
FT                                {ECO:0000269|PubMed:8068620,
FT                                ECO:0000303|PubMed:8068621}.
FT   REGION      194    196       Substrate binding.
FT                                {ECO:0000269|PubMed:8068620}.
FT   METAL        70     70       Magnesium 1; catalytic.
FT                                {ECO:0000269|PubMed:23027737,
FT                                ECO:0000269|PubMed:8068621,
FT                                ECO:0000303|PubMed:1332026,
FT                                ECO:0000303|PubMed:8068620}.
FT   METAL        90     90       Magnesium 1; catalytic.
FT                                {ECO:0000269|PubMed:23027737,
FT                                ECO:0000269|PubMed:8068621,
FT                                ECO:0000303|PubMed:1332026,
FT                                ECO:0000303|PubMed:8068620}.
FT   METAL        90     90       Magnesium 2.
FT                                {ECO:0000269|PubMed:23027737,
FT                                ECO:0000269|PubMed:8068621}.
FT   METAL        92     92       Magnesium 1; via carbonyl oxygen;
FT                                catalytic. {ECO:0000269|PubMed:23027737,
FT                                ECO:0000269|PubMed:8068621,
FT                                ECO:0000303|PubMed:1332026,
FT                                ECO:0000303|PubMed:8068620}.
FT   METAL        93     93       Magnesium 2.
FT                                {ECO:0000269|PubMed:23027737,
FT                                ECO:0000269|PubMed:8068621}.
FT   METAL       220    220       Magnesium 2.
FT                                {ECO:0000269|PubMed:23027737,
FT                                ECO:0000269|PubMed:8068621}.
FT   BINDING      70     70       Substrate. {ECO:0000269|PubMed:8068620,
FT                                ECO:0000303|PubMed:8068621}.
FT   BINDING     213    213       Substrate. {ECO:0000269|PubMed:8068620,
FT                                ECO:0000303|PubMed:8068621}.
FT   BINDING     220    220       Substrate. {ECO:0000269|PubMed:8068620}.
FT   MOD_RES     168    168       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1      1       M -> MGQRPGPVLPAVAVLGQVAKRKVAWLLRWKAVTRTE
FT                                TAGNSSGVYGFGKMKIFVKYFQKM (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046308.
FT   VAR_SEQ     153    277       DITKSLLVTELGSSRTPETVRMVLSNMEKLFCIPVHGIRSV
FT                                GTAAVNMCLVATGGADAYYEMGIHCWDVAGAGIIVTEAGGV
FT                                LMDVTGGPFDLMSRRVIAANNRILAERIAKEIQVIPLQRDD
FT                                ED -> GSGVLEQQLLICALWQLAEQMHIMKWEFTAGMLQE
FT                                LALLLLKLVAC (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042521.
FT   VARIANT     109    109       I -> V (in dbSNP:rs204781).
FT                                /FTId=VAR_049600.
FT   MUTAGEN      36     36       K->Q: 50-fold reduction in activity.
FT                                {ECO:0000269|PubMed:8718889}.
FT   MUTAGEN      93     93       D->N: Loss of activity.
FT                                {ECO:0000269|PubMed:17068342}.
FT   MUTAGEN     165    165       S->A,I: Reduced enzyme activity with myo-
FT                                inositol 1-phosphate.
FT                                {ECO:0000269|PubMed:8068620}.
FT   MUTAGEN     213    213       E->Q: Strongly reduced affinity for myo-
FT                                inositol 1-phosphate and strongly reduced
FT                                enzyme activity with myo-inositol 1-
FT                                phosphate. {ECO:0000269|PubMed:8068620}.
FT   HELIX         4     26       {ECO:0000244|PDB:4AS4}.
FT   STRAND       34     38       {ECO:0000244|PDB:4AS4}.
FT   STRAND       41     43       {ECO:0000244|PDB:4AS4}.
FT   HELIX        45     61       {ECO:0000244|PDB:4AS4}.
FT   STRAND       66     69       {ECO:0000244|PDB:4AS4}.
FT   HELIX        70     74       {ECO:0000244|PDB:4AS4}.
FT   STRAND       86     93       {ECO:0000244|PDB:4AS4}.
FT   HELIX        95    100       {ECO:0000244|PDB:4AS4}.
FT   STRAND      106    113       {ECO:0000244|PDB:4AS4}.
FT   STRAND      116    124       {ECO:0000244|PDB:4AS4}.
FT   TURN        125    128       {ECO:0000244|PDB:4AS4}.
FT   STRAND      129    134       {ECO:0000244|PDB:4AS4}.
FT   TURN        135    137       {ECO:0000244|PDB:4AS4}.
FT   STRAND      138    141       {ECO:0000244|PDB:4AS4}.
FT   HELIX       154    156       {ECO:0000244|PDB:4AS4}.
FT   STRAND      158    160       {ECO:0000244|PDB:4AS4}.
FT   HELIX       169    183       {ECO:0000244|PDB:4AS4}.
FT   TURN        184    186       {ECO:0000244|PDB:4AS4}.
FT   STRAND      188    192       {ECO:0000244|PDB:4AS4}.
FT   HELIX       196    204       {ECO:0000244|PDB:4AS4}.
FT   STRAND      207    215       {ECO:0000244|PDB:4AS4}.
FT   HELIX       218    230       {ECO:0000244|PDB:4AS4}.
FT   STRAND      234    236       {ECO:0000244|PDB:4AS4}.
FT   STRAND      240    242       {ECO:0000244|PDB:1IME}.
FT   STRAND      247    255       {ECO:0000244|PDB:4AS4}.
FT   HELIX       256    265       {ECO:0000244|PDB:4AS4}.
SQ   SEQUENCE   277 AA;  30189 MW;  861D5617E1C04627 CRC64;
     MADPWQECMD YAVTLARQAG EVVCEAIKNE MNVMLKSSPV DLVTATDQKV EKMLISSIKE
     KYPSHSFIGE ESVAAGEKSI LTDNPTWIID PIDGTTNFVH RFPFVAVSIG FAVNKKIEFG
     VVYSCVEGKM YTARKGKGAF CNGQKLQVSQ QEDITKSLLV TELGSSRTPE TVRMVLSNME
     KLFCIPVHGI RSVGTAAVNM CLVATGGADA YYEMGIHCWD VAGAGIIVTE AGGVLMDVTG
     GPFDLMSRRV IAANNRILAE RIAKEIQVIP LQRDDED
//
